| Entry |
|
|---|
| Name |
Patritumab deruxtecan (USAN/INN);
Patritumab deruxtecan (genetical recombination) (JAN) |
|---|
| Formula |
C6542H10072N1740O2038S40. (C52H56FN9O13)n
|
|---|
| Remark |
|
|---|
| Efficacy |
Antineoplasitc |
|---|
| Type |
Antibody-drug conjugate |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FX Other monoclonal antibodies and antibody drug conjugates
L01FX36 Patritumab deruxtecan
D12184 Patritumab deruxtecan (USAN/INN)
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
ERBB3 (HER3)
D12184 Patritumab deruxtecan (USAN/INN)
Enzymes
Isomerases (EC5)
DNA topoisomerase
TOP1
D12184 Patritumab deruxtecan (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
